Atara Biotherapeutics (AT20) Ownership - Who Owns Atara Biotherapeutics?
Atara Biotherapeutics (AT20) Ownership Overview
- 51.23% Insiders
- 5.09% Mutual Funds
- <0.01% Other Institutional Investors
- 2.73% ETFs
- 40.95% Public Companies and Individual Investors
The ownership structure of Atara Biotherapeutics (DE:AT20) stock is a mix of institutional, retail, and individual investors. Approximately 7.81% of the company’s stock is owned by Institutional Investors, 51.23% is owned by Insiders, and 40.95% is owned by Public Companies and Individual Investors.
The ownership structure of Atara Biotherapeutics (DE:AT20) stock is a mix of institutional, retail, and individual investors. Approximately 7.81% of the company’s stock is owned by Institutional Investors, 51.23% is owned by Insiders, and 40.95% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Sep 03, 2026 | Brian Cherry | $999,994 | |
| Aug 25, 2026 | Anhco Nguyen | $40,850 | |
| May 19, 2026 | Yanina Grant-huerta | $22,016 | |
| May 19, 2026 | Anhco Nguyen | $47,798 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Ecor1 Capital, Llc | 1,552,000 | Insider | 15.46% | 12,651,904 |
| Panacea Innovation Limited | 1,318,894 | Insider | 13.14% | 10,751,624 |
| Gregory Austin Ciongoli | 1,221,395 | Insider | 12.17% | 9,956,812 |
| Redmile Group, Llc | 636,852 | Insider | 6.34% | 5,191,618 |
| Vanguard | 241,404 | Institution | 2.40% | 1,967,925 |
| Vanguard Index Funds | 241,404 | Institution | 2.40% | 1,967,925 |
| Brian Cherry | 166,486 | Insider | 1.66% | 1,357,194 |
| Fidelity Commonwealth Trust Ii | 141,924 | Institution | 1.41% | 1,156,964 |
| Anhco Nguyen | 132,775 | Insider | 1.32% | 1,082,382 |
| BlackRock, Inc. | 84,455 | Institution | 0.84% | 688,477 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 241,404 | Institution | 2.40% | 1,967,925 |
| Fidelity Commonwealth Trust Ii | 141,924 | Institution | 1.41% | 1,156,964 |
| Fidelity Concord Street Trust | 63,376 | Institution | 0.63% | 516,641 |
| Northern Funds | 32,012 | Institution | 0.32% | 260,962 |
| Bridgeway Funds, Inc. | 14,000 | Institution | 0.14% | 114,128 |
| Victory Portfolios Iii | 10,318 | Institution | 0.10% | 84,112 |
| Vanguard Institutional Index Funds | 2,844 | Institution | 0.03% | 23,184 |
| Vanguard Valley Forge Funds | 2,799 | Institution | 0.03% | 22,817 |
| Schwab Capital Trust | 1,643 | Institution | 0.02% | 13,394 |
| John Hancock Variable Insurance Trust | 210 | Institution | <0.01% | 1,712 |
FAQ
Who Owns Atara Biotherapeutics (DE:AT20)?
According to the latest TipRanks data, approximately 7.81% of the company's stock is held by institutional investors, 51.23% is held by insiders, and 40.95% is held by public companies and individual investors.
What percentage of Atara Biotherapeutics (DE:AT20) stock is held by institutional investors?
According to the latest TipRanks data, approximately 7.81% of Atara Biotherapeutics (DE:AT20) stock is held by institutional investors: 5.09% by mutual funds, 2.73% by ETFs and <0.01% by other institutional investors.
What percentage of Atara Biotherapeutics (DE:AT20) stock is held by retail investors?
According to the latest TipRanks data, approximately 40.95% of Atara Biotherapeutics (DE:AT20) stock is held by public companies and individual investors.
Who owns the most shares of Atara Biotherapeutics (DE:AT20)?
Ecor1 Capital, Llc owns the most shares of Atara Biotherapeutics (DE:AT20).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
